Antimalarial Drugs Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2025 – 2034

Antimalarial Drugs Market Size

The global antimalarial drugs market generated notable revenues in 2024 and is anticipated to grow at a decent CAGR from 2025 to 2034, propelled by the increase in cases of Malaria, a severe illness caused by Plasmodium parasites delivered by bites from infected mosquitoes. As per WHO, an estimated 263 million cases and 597,000 malaria-related deaths globally took place.  The increasing cases of malaria incidence, coupled with the resistance to current antimalarial drugs in a healthcare system that is not adequately developed to deal with endemic disease has led to demand for new therapies.
 

The growth of the antimalarial drug market has been mainly attributed to the increase in the incidence of malaria treatment considerations, government action, and awareness of adequate treatment and prevention. Subsequently, the opportunity to develop new forms of drug formulations and combination therapies, as well as ongoing research efforts to find new ways to combat drug-resistant vector-borne disease will positively alter the landscape of the antimalarial drug market from a growth perspective.
 

A major restraining factor in the antimalarial drugs market is the ever-increasing problem of drug resistance. The emergence of resistance against commonly used antimalarial drugs, like artemisinin-based combination therapies (ACTs), is a significant challenge to the effective management of malaria.
 

To enhance their global presence in the market, companies have been focusing on a number of strategies. First, major pharmaceutical companies have dedicated their research and development (R&D) capabilities to develop new and more effective treatments, especially combating drug-resistant malaria strains. New drug classes, along with innovative drug combinations, are currently being evaluated to ensure higher efficacy with shorter treatment durations.
 

Antimalarial Drugs Market Trends

There have been notable trends in the market in recent years, many of which stem from changes in drug formulations, an increased emphasis on research into drug-resistant malaria, and the continued global push to eradicate malaria. The introduction of combination therapies including ACTs (Artemisinin-Combination Therapies) as the mainstay of malaria treatment is likely to be top among the trends that have been able to demonstrate their effectiveness for treating multidrug-resistant malaria strains.
 

In the same vein, there is increasing interest in long-acting injectable formulations intended to minimize treatment regimens while maximizing patient adherence, especially for patients in the developing world when seeking to maintain access to care and treatment such as antimalarial drugs, long-standing injectable formulations that remain in the body and release antimalarial medicine for an extended term could fulfill a gap in the market. The development of next-generation antimalarial drugs that target new mechanisms of parasite resistance could potentially result in more effective treatments for resistant strains, such as Plasmodium falciparum. Additionally, vaccine development is on the rise, and products such as the RTS, and S/AS01 malaria vaccine have shown reduced incidence of viruses and, thus have implications for the existing strategy to work towards eradicating malaria worldwide.
 

Antimalarial Drugs Market Analysis

The hydroxychloroquine segment held the largest share in 2024 and is projected to hold its leading position through 2034. It was created and approved to treat autoimmune diseases which included rheumatoid arthritis and lupus but has been employed in the treatment of malaria. Hydroxychloroquine is antimalarial, which generates efficacy by killing the Plasmodium malaria parasite that forms the malaria illness and affects humans. Hydroxychloroquine generates efficacy in the treatment of malaria by significantly inhibiting the parasite's use of hemoglobin in the cysts of red blood cells, thus killing the parasite from the malaria illness. Hydroxychloroquine is the leading and most efficacious treatment against uncomplicated malaria by the deadliest malarial parasite Plasmodium falciparum in all cases. Hydroxychloroquine is used in the treatment of malaria, without exception, in combination with one or more antimalarials including chloroquine or azithromycin to develop resistance and increase efficacy.  
 

The treatment segment in the antimalarial drugs market is likely to generate significant revenues until 2034, primarily because the treatment of malaria will fit into only two categories: first-line therapy and second-line therapy. First-line therapy is usually a combination of medications and frequently ACTs (artemisinin-based combination therapies). First-line therapy is considered the best choice for treating malaria due to Plasmodium falciparum. All combinations help address one of the challenges with antimalarial therapy which is resistance and failure to treat over time.
 

Second-line therapies are used when there is resistance to the first line of therapies or when the patient has no response to the first line of therapy. These stimulants could include depending on the region of the patient, and the strain of malaria, ACT s, chloroquine, quinine, etc. The unified global effort to improve identification and interaction addressing malaria has accomplished an extraordinary amount of work, if you will, regarding the formulation and development of antimalarial drugs. It is encouraging that the multiple antimalarial drugs are used in fixed-dose combinations which promote even more thorough eradication of the parasites facilitating, of course, even less drug resistance. In addition, there are also works in every field of investigation to bring new drugs to market that have faster-acting and accepted side effects such that inordinate periods of treatment do not produce undue patient concern and/or non-compliance.
 

United States antimalarial drugs market held the largest share in 2024 due to a developed healthcare system focusing on patient care, a developed pharmaceutical industry, and a commitment to researching global public health challenges like malaria. Generally, malaria is rare in the U.S., primarily due to public health measures and travel to areas where malaria is endemic though it is widely recognized that there is a strong market force for antimalarial drugs. Almost all U.S. pharmaceutical companies develop, produce, and distribute antimalarial drugs and treatments worldwide.
 

The U.S. government has funded international malaria control efforts and partnerships with organizations like the World Health Organization (WHO) and the Global Fund to Fight AIDS, Tuberculosis, and Malaria. U.S. pharmaceutical companies including Gilead Sciences and Merck have been key players in the research and development of new drugs and drug combinations for treating malaria. There are already other drugs with the potential to replace current malaria drug treatments due to humans getting resistance to these drugs or at a minimum provide treatments for human malaria infections that have drug resistance.
 

Antimalarial Drugs Market Share

Major antimalarial drug industry includes:

• Teva Pharmaceutical
• Zydus Cadila
• Cipla
• Mylan
• Strides Pharma Science Limited
• Novartis
• Bayer
• F. Hoffmann-La Roche Ltd.
• Ipca Laboratories
• Lincoln Pharmaceuticals
• Glenmark Pharmaceuticals
• GlaxoSmithKline
• Alliance Pharma
   

To increase their global enterprise in the market companies have been focused on various strategies. First, many companies' R&D (research and development) departments are working to develop new and improved antimalarial therapies, especially focusing on new treatments for drug-resistant malaria. New classes of drugs, and new combinations of drugs, are currently in worldwide clinical trials to create drugs with better efficacy with less therapy duration.
 

Second, companies have identified partnerships and collaborations with international health organizations and governments to be extremely important in creating and disseminating improved treatments for malaria. Companies (e.g. Novartis, GSK, and Sanofi) have partnered with organizations (e.g. WHO, Global Fund), to distribute antimalarial drugs in malaria-endemic countries to improve their support for global eradication initiatives.
 

Antimalarial Drugs Industry News

• In July 2024, the SAFIRE consortium, conducted a Phase III clinical trial to evaluate antimalarial medicines during early pregnancy. The trial aimed to assess the safety, tolerability, and cost-effectiveness of antimalarial drugs for women in their first trimester, specifically for the treatment of uncomplicated malaria. 
   
• In July 2024, GSK and Medicines for Malaria Venture (MMV) launched tafenoquine, a new single-dose medicine designed to prevent the relapse of Plasmodium vivax malaria in malaria-endemic countries such as Brazil and Thailand.